Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a global medical technology company focused on surgical solutions for spinal, orthopedic, and wound care disorders, with a portfolio centered on orthobiologics and spinal implant systems. The XTNT news feed on Stock Titan aggregates company-issued updates and regulatory disclosures so readers can follow how Xtant communicates its strategy, product launches, and financial performance.
Recent news releases describe Xtant’s emphasis on its core biologics business and regenerative medicine capabilities. The company has announced the commercial launch of products such as CollagenX™, a bovine collagen particulate product for surgical wound closure, and OsteoFactor Pro™, a growth factor-based biologic designed to improve bone healing across orthopedic and spine procedures. Xtant has also introduced Trivium™, a next-generation demineralized bone matrix allograft, and nanOss Strata™, a synthetic bone graft manufactured from hydroxycarbonapatite and designed to mimic human bone structure and support osteoconductivity and cellular activity.
Company news also covers strategic transactions and portfolio changes. Xtant has reported entering into, and subsequently completing, the sale of certain non-core Coflex and CoFix spinal implant assets and its Paradigm Spine GmbH international hardware business to Companion Spine entities, describing these divestitures as a way to sharpen its focus on biologics and strengthen its balance sheet.
Investors and analysts following XTNT news will find quarterly earnings announcements, including revenue trends, gross margin, net income, adjusted EBITDA, and cash flow metrics, as well as financial guidance for the year. The company also issues notices about participation in investor conferences, annual meeting details, and governance developments such as changes to its Board of Directors and amendments to equity incentive plans.
By reviewing the XTNT news stream, readers can see how Xtant presents its mission of honoring the gift of donation, its product development priorities in orthobiologics and wound closure, and the financial and strategic milestones it reports through press releases and SEC-related communications.
Xtant Medical Holdings, Inc. (XTNT) reported Q1 2021 results, with revenue of $12.5 million, a decrease from $14.8 million in Q1 2020, mainly due to COVID-19 impacts. Operating expenses fell to $8.1 million from $11.0 million as a result of lower sales and wages. The company incurred a net loss of $29,000, a significant improvement from $2.5 million in the prior period. Non-GAAP Adjusted EBITDA rose to $0.8 million from $0.3 million. Xtant raised $18.4 million from a private placement and secured $20 million in debt refinancing to bolster growth initiatives.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has filed a universal shelf registration statement on Form S-3 with the SEC, allowing the company to offer and sell various securities up to $150 million over three years. This filing is aimed at enhancing capital market access for financing growth initiatives. Additionally, it permits OrbiMed Advisors, LLC to sell up to 18,218,374 shares of XTNT common stock. The company currently has no specific plans for issuing securities under this registration, and proceeds from any stock sales will not benefit Xtant directly.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has entered into new credit agreements with MidCap Financial Trust, which include a $12 million secured term loan at 7% interest and an $8 million secured revolving credit facility at 4.5% interest. These agreements replace the existing loan from OrbiMed, fully repaying that debt. The new financing is aimed at enhancing the company's balance sheet and supporting strategic growth initiatives.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its Q1 2021 financial results on May 11, 2021, before market open. A conference call, led by CEO Sean Browne and CFO Greg Jensen, will take place at 9:00 AM ET on the same day to discuss the results. Interested parties can join the call using the provided dial-in numbers or register for the webcast. The company specializes in surgical solutions for spinal disorders, including orthobiologics and spinal implant systems.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that it is not aware of any undisclosed corporate developments accounting for the recent surge in its share price and trading volume. The company focuses on surgical solutions for spinal disorders, offering a range of orthobiologics and spinal implant systems. Their commitment to integrity and customer service remains a priority as they navigate the market fluctuations.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has successfully closed a $20 million private placement with a healthcare-focused institutional investor. The deal involved the sale of 8,888,890 common shares and warrants for 6,666,668 shares, at a price of $2.25 each. Net proceeds after fees are approximately $18.4 million, intended for working capital and other corporate purposes. The warrants are exercisable at the same price, expiring in five years. Sean Browne, President and CEO, expressed that this funding will support growth initiatives and enhance shareholder value.
Xtant Medical Holdings, Inc. (XTNT) reported fourth quarter 2020 revenue of $14.0 million, down from $17.0 million a year earlier, primarily impacted by COVID-19. However, operating expenses decreased to $8.7 million from $11.7 million, leading to a narrower net loss of $0.7 million or $0.01 per share, compared to a loss of $1.6 million in Q4 2019. The company announced a $20 million private placement to enhance working capital. Despite revenue declines, there is positive momentum toward recovery as elective procedures rebound.
Xtant Medical Holdings (NYSE American: XTNT) has entered into a definitive agreement for a private placement to raise approximately $20 million. The agreement includes the sale of 8,888,890 common shares and warrants to purchase 6,666,668 common shares, priced at $2.25 each. Proceeds will be used for working capital and corporate purposes. The placement is expected to close around February 24, 2021, pending regulatory approvals. A.G.P./Alliance Global Partners is the sole placement agent.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its financial results for the fourth quarter and full year ended December 31, 2020, on February 24, 2021, before market open. The results will be discussed in a conference call at 9:00 AM ET the same day, led by CEO Sean Browne and CFO Greg Jensen. Investors can join the call at 877-407-6184 or through international dial-in at 201-389-0877. A replay will be available on the company's website post-call. Xtant Medical specializes in surgical solutions for spinal disorders.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that the subscription period for its rights offering expired on December 4, 2020. The company expects to issue approximately 711,143 shares at a subscription price of $1.07, generating gross proceeds of around $761,000. This is based on preliminary results from EQ Shareowner Services. The offering's final results await verification. The company’s SEC registration statement was effective as of November 3, 2020. Interested parties can find more details on the SEC's website.